FDA approvals, research breakthroughs, clinical trials, and advocacy updates
Curated and summarized by AI for patients and caregivers
17 articles from the last 30 days matching "european medicines"
The European Medicines Agency approved a new veterinary vaccine called Nobivac NXT HC. This vaccine helps protect animals through active immunization. This is a veterinary medicine approval, not a human medicine.
The European Medicines Agency has approved a new medicine called Jascayd (nerandomilast) to treat adults with two types of lung scarring diseases: idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease. This approval means the medicine is now available for patients in the European Union. This is the first time this particular medicine has been approved for these conditions in Europe.
The European Medicines Agency approved eight new medicines in May 2026. The article mentions a few specific drugs, including Jascayd (nerandomilast) and Boey (trenibotulinumtoxinE), though details about what diseases they treat are incomplete in this announcement.
The European Medicines Agency (EMA) will be closed on Monday, May 25, 2026, for Whit Monday, a public holiday. The office will reopen at 8:30 AM on Tuesday, May 26. If you need emergency help with medicines during this time, a special hotline will still be available.
The European Medicines Agency (EMA) is closely watching an outbreak of Andes hantavirus that started on a cruise ship. Hantavirus is a serious infection spread by infected rodents that can cause severe lung and kidney problems in people. The EMA is working with other European health organizations to monitor the situation and make sure patients get proper treatment.
The European Medicines Agency (EMA) will be closed for a holiday weekend from the evening of May 13 through the morning of May 18, 2026. However, there is still an emergency hotline available if patients need urgent help with medicines during this time.
The European Medicines Agency (EMA) announced that European lawmakers have agreed on a new Critical Medicines Act to make sure important medicines don't run out across Europe. This law was created because Europe has faced medicine shortages in recent years, especially during the COVID-19 pandemic and other global problems. The agreement aims to create stronger and more reliable ways to produce and deliver medicines that people need.
The European Medicines Agency (EMA) created a new advisory group to address vaccine hesitancy—when people are unsure about getting vaccines. The group will meet four times a year and includes doctors, patient representatives, and other experts. Their goal is to help the EMA understand why people distrust vaccines and find ways to rebuild confidence in vaccine safety.
The European Medicines Agency (EMA) will be closed on April 27, 2026 for King's Day in the Netherlands and on May 1, 2026 for Labour Day. During these closures, the EMA's regular office services will not be available. Patients and healthcare providers should plan ahead if they need to contact the EMA during these dates.
The European Medicines Agency held its monthly safety meeting in May 2026 to review how medicines are being used and whether they're causing any unexpected side effects. The committee looked at new safety concerns and checked on medicines already approved in Europe to make sure they're still safe for patients.
The European Medicines Agency has updated its recommendations for which flu virus strains should be included in flu vaccines for the 2026-2027 season. These recommendations apply to different types of flu vaccines, including those made using eggs and live weakened virus versions. The update was announced in May 2026 to help vaccine manufacturers prepare the right vaccines for the upcoming flu season.
The European Medicines Agency (EMA) has started a new pilot program to help companies develop breakthrough medical devices faster in Europe. This program tests new ways to review and approve devices that could help patients with serious conditions. The goal is to make it easier for innovative medical tools to reach patients who need them.
The European Medicines Agency has approved a new medicine called Redemplo (plozasiran) for adults with familial chylomicronaemia syndrome (FCS), a rare genetic condition where the body cannot properly break down certain fats in the blood. This medicine helps reduce triglycerides, which are a type of fat that builds up to dangerous levels in people with FCS. The approval means the medicine is now available for patients in the European Union.
The European Medicines Agency approved a new veterinary vaccine called Nobivac NXT HCPChFeLV. This vaccine helps protect cats from three common infectious diseases. This approval is for animal use only, not for human patients.
The European Medicines Agency has approved a new vaccine for cats called Nobivac NXT HCPChFeLV that uses RNA technology to protect against common cat diseases. This is the first veterinary vaccine using this newer RNA technology approach. The vaccine can now be sold and used in European Union countries.
The European Medicines Agency's committee met in April 2026 and recommended five new medicines for approval in Europe. One of these medicines is called Cenrifki (tolebrutinib), though the article doesn't provide complete details about what diseases these medicines treat. This is a routine announcement about medicines moving forward in the approval process.
A European health committee has recommended that Agamree, a medicine for Duchenne muscular dystrophy (DMD), be approved for use in younger children starting at age 2. Previously, the drug was approved for older children and adults. This recommendation means more DMD patients in Europe could potentially access this treatment if the European Medicines Agency approves the committee's suggestion.
Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.